Articles

Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.

T1D Exchange Registry - A User-Friendly Way to Participate in Type 1 Diabetes Research

The T1D Exchange Registry is a collection of individuals with type 1 diabetes and their supporters who participate in research. Adults with type 1 diabetes or parents of children with type 1 diabetes can join by registering online, providing consent, and completing a short 28-question survey. Participants will then be asked to complete a similar questionnaire once a year. Once registered, participants will also have the ability to take part in more research opportunities in the future.

Tandem t:slim X 2 pump with control IQ technology

Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.

Fiasp fast acting insulin pen

The U.S. Food and Drug Administration has approved Novo Nordisk's fast-acting Fiasp insulin for use in children as well as adults, the pharmaceutical firm announced Monday.

A patient loads insulin for his routine shot.

At least 17 states have passed laws carving out exceptions for pharmacists to fill insulin prescriptions during emergency situations. These legal reforms are seen by some advocates as the first real sign of progress for improved access to insulin in the United States.

Type 1 Diabetes Exercise Study

We wanted to share some information with you about a new research study. The Type 1 Diabetes EXercise Initiative is a 4-week at-home study. We hope that the study will help us learn how blood sugar changes during exercise in people with type 1 diabetes.  If you join the study, you will be asked to …

logo for French pharma manufacturer Sanofi

Sanofi, the French pharmaceutical giant which manufactures the long-acting insulin Lantus, announced Monday that it would no longer be investing in research for new drugs to treat diabetes. The manufacturer also told investors it would no longer be investigating new treatments for cardiovascular health. “To be out of cardiovascular and diabetes is not easy for …

T1D Exchange is conducting interviews with caregivers of people with type 1 diabetes who are 55 and over in the United States. The interview will be a semi-structured one-to-one phone interview with a diabetes professional to discuss your perspective and experience providing care for adult patients with type 1 diabetes.

To help get the word out about the Registry and the opportunities it offers to participate in research, members of the Registry team here at T1D Exchange traveled to a range of type 1 diabetes events, walks, and other gatherings.

Kobi, a young woman living with type 1 diabetes in Florida, spoke with us at Friends for Life about her experiences with diabetes and the massive changes she’s seen in her lifetime.